Intuitive Surgical Demonstrates Strong 17% Procedure Growth Amid International Mixed Results
Q1 2026 Earnings Call, April 21, 2026
Intuitive Surgical delivered a solid first quarter with 17% total procedure growth, though the performance revealed a tale of two markets: robust strength in the United States and Europe contrasted against ongoing headwinds in China and Japan. The company raised its full-year da Vinci procedure growth guidance to 13.5% to 15.5% from 13% to 15%, while also lifting gross margin expectations despite persistent macro pressures.
The quarter's 23% revenue growth notably outpaced procedure growth, a dynamic management highlighted as "innovation-led revenue performance" driven primarily by the differentiated value of da Vinci 5. This disconnect between revenue and procedure growth reflects a strategic focus on premium pricing for differentiated products while selectively sharing cost savings in more price-sensitive markets.
Domestic Strength Driven by General Surgery and After-Hours Expansion
United States da Vinci procedures grew 14% year-over-year, with general surgery leading the way. Management called out particularly strong 31% growth in after-hours procedures, which contributed to a 4% increase in da Vinci utilization in the U.S., exceeding recent quarters. This utilization improvement was driven by a growing installed base of da Vinci 5 systems, where utilization runs approximately 11% higher than Xi systems.
Within general surgery, cholecystectomy and appendectomy procedures combined grew 31%. For the first time, management explicitly highlighted emerging evidence that appendectomy outcomes are improved with da Vinci surgery compared to laparoscopy. CEO Dave Rosa noted that "over the last year, in the U.S., we've invested in incremental clinical support for surgeons performing benign gynecology procedures," which drove 19% growth in non-hysterectomy benign procedures including sacrocolpopexy, endometriosis, oophorectomy and myomectomy.
The bariatric headwind persisted, with U.S. da Vinci bariatric procedures declining approximately 10% due to continued GLP-1 adoption. Management noted they did not see significant impact from the expiration of ACA premium subsidies in Q1, though they remain cautious about potential future effects.
International Growth Marred by China and Japan Challenges
Outside the United States, da Vinci procedures grew 19%, reflecting strong results in India, Canada, the U.K., Korea and Taiwan. However, this marked a deceleration from prior quarters, with China and Japan representing the primary drags. CFO Jamie Samath stated directly that in China, "the environment remains largely consistent with recent quarters reflecting relatively low tender activity across the category, domestic competition and policy-driven pricing pressure."
The company placed just four systems in China during the quarter. While management noted ongoing discussions with provinces regarding potential new charge code and reimbursement policies, Samath was clear that "we do not expect clarity on the outcome of these matters until 2027." This represents a frank acknowledgment that the China headwind is likely to persist through at least the remainder of 2026.
Japan showed modest sequential improvement but remained below historical levels following fewer system placements in 2025. The Japanese Ministry of Health, Labor and Welfare introduced incremental reimbursement for hospitals exceeding 200 robotic procedures per year, granted reimbursement for seven new procedures starting in June 2026, and provided premium reimbursement for rectal resection when performed robotically. The largest new procedure covered is bilateral inguinal hernia repair at roughly $1,500 per procedure. However, management remained cautious, with Samath noting concerns about "the financial position of public hospitals in recent periods."
Capital Performance Reflects Geographic Disparities
Intuitive placed 431 da Vinci systems in Q1, up 17% from 367 in the prior year period. This included 232 da Vinci 5 systems, bringing the installed base to almost 1,500 systems used by nearly 13,000 surgeons since launch. Notably, the company placed 34 refurbished Xi systems, up from just two in the year-ago period, with 26 of these placements in international markets management characterized as having "greater cost sensitivity."
The refurbished Xi strategy represents a deliberate tiered approach to meet varying customer needs. Samath emphasized that "that is a very capable product. It has the full complete suite in the ecosystem and the economics for customers are really attractive." This product segmentation provides Intuitive with flexibility to compete against lower-priced entrants in cost-sensitive markets while maintaining premium positioning for da Vinci 5.
Trade-in transactions reached 119 in the quarter, up from 67 a year ago, primarily driven by U.S. customers upgrading to da Vinci 5. The leasing mix increased to 56% of placements from 47% last quarter, driven by customer preference.
Single Port and Ion Deliver Strong Growth
The SP platform continued momentum with 68% procedure growth, driven by expansion in Korea and the United States along with early adoption across select international markets. U.S. surgeons performed the first non-IDE nipple-sparing mastectomy cases, an important TAM-expanding opportunity that management suggested may be underestimated. Average U.S. SP system utilization grew 22% year-over-year.
The company moved its single-port stapler into broad launch in the U.S., where it was used in almost 40% of cases where a stapler would be expected. Management plans to move the SP stapler into measured launch in Korea and Europe in Q2 as manufacturing capacity expands. Looking forward, management noted that "over the midterm, SP will incorporate much of the da Vinci 5 ecosystem, including current and future digital and AI capabilities."
Ion procedures increased 39% to 43,000, with 52 system placements in the quarter. A significant Mayo Clinic publication in Mayo Clinic Proceedings provided compelling evidence of Ion's value proposition. The study of 2,115 peripheral pulmonary lesions from 1,904 patients demonstrated 79% diagnostic yield under strict consensus definition with 85% sensitivity for malignancy. The pneumothorax requiring intervention rate was just 1.4%. Notably, the rate of early-stage primary lung cancer diagnosis increased 23 percentage points from 46% in 2019 to 69% in 2024.
Margin Performance Reflects Cost Progress and Tariff Impact
Non-GAAP gross margin reached 67.8%, up from 66.4% in the prior year, reflecting product cost reductions and fixed overhead leverage partially offset by tariff impacts. Management achieved an important milestone with da Vinci 5 system contribution margins now comparable to Xi systems, while Ion platform contribution margins approached the corporate average.
The company updated non-GAAP gross margin guidance to 67.5% to 68.5%, which now reflects 100 basis points of tariff impact, down from the 120 basis points assumed in January. However, this improvement was offset by higher input costs in freight and semiconductor memory. Samath noted that while Q1 results were not significantly impacted by higher oil and memory prices, "we do expect those to have a greater unfavorable impact in the remainder of the year."
Operating expenses increased 10% year-over-year, slightly below expectations due to timing. The company added 425 employees during the quarter, with 230 related to the acquisition of the distribution business in Italy, Spain and Portugal. Full-year operating expense growth guidance increased to 11% to 14%.
Innovation-Led Revenue Performance and Pricing Strategy
The 23% revenue growth against 17% procedure growth represents a significant delta that management took time to explain. Samath articulated what he termed "innovation-led revenue performance," stating: "We're very conscious about deploying our R&D to places where we can be differentiated and make a difference on the Quintuple Aim. And so where you can be differentiated and make a real difference for customers, then you get to sharing that value in the form of accretive pricing or incremental pricing."
This dynamic is evident in da Vinci 5, SP instruments and accessories, and anticipated future products like the SP stapler and vessel sealer. On the other side, management noted they share cost savings with customers in more cost-sensitive procedures and geographies "particularly in mind with what can be the elasticity response." This creates a deliberate mix dynamic that has sustained revenue growth ahead of procedures.
Da Vinci instruments and accessories per procedure reached approximately $1,880 compared to $1,780 last year, driven by customer ordering patterns, higher mix of SP and da Vinci 5 procedures, and favorable foreign exchange, partially offset by lower bariatric and higher cholecystectomy procedures.
Digital and AI Roadmap Takes Shape
Management provided the most detailed articulation to date of Intuitive's approach to artificial intelligence and digital capabilities. Rosa outlined a layered approach beginning with high-quality data from video, robotic data streams like kinematics and force data, and connected electronic medical records. The goal is to turn this into "meaningful insights" delivered to customers "in a consumable fashion at the right time in the moment that matters."
The applications will span operational guidance for hospital programs, learning support for surgeons and care teams, and most significantly, in-surgery assistance. Rosa described a phased approach: "An example of this kind of first phase might be AI-enabled anatomy identification where you can see AI showing critical structures in the surgical field, showing tissue planes to help assist the surgeon. Then, over time, what we expect is that many of those same foundations will support more advanced assistance around augmented dexterity and it will include aspects of automation."
The company now has approximately 1,500 da Vinci 5 systems generating data from more than 3 million annual procedures. Management views this unique dataset, particularly force feedback data, as a key competitive advantage in the AI era. Rosa noted that telecollaboration capabilities within My Intuitive+ are already seeing "thousands of use cases a month," with telesurgery expected to represent a future subset of these interactions.
Force Feedback Instruments Scale Up
In March, Intuitive received FDA 510(k) clearance for additional uses of Force Feedback instruments. Five of six instruments are now cleared for 15 uses, while the Mega SutureCut Needle Driver is cleared for 10 uses. Combined with supply chain and manufacturing investments, this clearance supports broader availability beginning in Q2 that will increase throughout the year. Management expects "adoption of Force Feedback instrumentation to progress steadily through 2026 and beyond."
At the recent SAGES conference, several clinical abstracts demonstrated objectively lower tissue forces using Force Feedback instrumentation across multiple procedure types. Rosa stated directly: "We continue to believe that objective knowledge of applied forces in surgery will lead to improved surgical outcomes and are investing to demonstrate this at scale."
Leadership Transition and Cybersecurity Incident
The company announced Dr. Myriam Curet's retirement after more than 20 years as Chief Medical Officer, with Dr. Jamie Wong promoted to the role. Wong brings a clinical background as a practicing da Vinci urologist and more than a decade of experience at Intuitive across various functions. As CMO, he will oversee global medical office activities including customer training, clinical evidence generation, and reimbursement and market access efforts.
Samath disclosed a cybersecurity incident during the quarter resulting in unauthorized access to some customer business and contact information as well as certain employee and corporate data. The incident "did not disrupt our business or manufacturing operations and did not affect our products. It also did not have a significant impact on our first quarter financial results." The company has contained the incident, notified affected parties, and is strengthening cybersecurity protocols.
Competition and Strategic Positioning
When asked about competitive dynamics with new entrants in the U.S., China and Europe, Rosa emphasized that competition is fundamentally about "meeting the needs of the customer at the right price point" and delivering program value rather than simply robot pricing. He stressed the importance of outcome improvements, shift from open to minimally invasive procedures, and the ecosystem of services and training.
Rosa stated: "When it comes to those conversations and the data that are shared, I expect with our portfolio and now with XiR added, that will be a strong choice to lead in those value because of the demonstrated clinical output, the reliability of our systems, our ecosystem of services and training." The addition of refurbished Xi systems provides what Samath called "a competitive advantage for us to be able to tier feature, the capability and economics for various segments of our customers."
The international strategy involves market-by-market localization including potential manufacturing in large markets, direct operations where opportunity warrants, and potentially franchising additional distributor markets not currently served. Management emphasized the multi-year nature of establishing value recognition with both customers and government reimbursement agencies in each geography.
Intuitive Surgical, Inc. Deep Dive
The Business Model and Revenue Mechanics
Intuitive Surgical operates what is arguably the most successful and resilient razor-and-blade business model in the modern medical technology landscape. The company designs, manufactures, and markets the da Vinci surgical system, the Ion endoluminal system, and the da Vinci SP single-port system. While the initial capital placement of a da Vinci robot carries a multi-million dollar price tag, typically ranging from $1.5 million to $2.5 million depending on the configuration, the true economic engine of the company lies in its recurring revenue streams. As of the first quarter of 2026, recurring revenue accounted for 86% of Intuitive Surgical’s total $2.77 billion quarterly top line.
This recurring revenue is derived primarily from the sale of instruments and accessories, alongside lucrative long-term service contracts. Every robotic procedure requires a specific set of single-use or limited-use instruments, such as forceps, scissors, and staplers, which attach to the robotic arms and must be replaced after a strict number of uses. Consequently, as global procedure volumes rise, instrument and accessory revenue scales proportionally and at very high gross margins. Furthermore, the company has increasingly shifted hospital customers toward flexible acquisition models, including operating leases, which further smooths out capital expenditure cycles and locks hospitals into long-term operational partnerships.
Customers, Competitors, and Supply Chain Dynamics
The primary customers for Intuitive Surgical are acute care hospitals, academic medical centers, and an increasingly important cohort of ambulatory surgery centers. By placing systems in these facilities, Intuitive serves end customers comprising patients undergoing minimally invasive surgical procedures across urology, gynecology, general surgery, thoracic, and cardiac disciplines. Ambulatory surgery centers represent a particularly vital growth vector as healthcare systems look to shift less complex procedures out of high-cost hospital environments.
On the supply chain side, Intuitive relies on highly specialized manufacturing processes requiring advanced semiconductor memory, precision mechanical components, and complex optical systems. The company maintains manufacturing facilities in California, alongside endoscope production in Germany and Bulgaria. However, this global supply chain exposes the company to geopolitical friction. Recent international trade tensions and resulting import tariffs placed significant pressure on the company, negatively impacting pro forma gross margins by approximately 95 basis points throughout 2025.
The competitive landscape in soft tissue robotics is intensifying after decades of Intuitive operating as an uncontested monopoly. The key challengers are highly capitalized, diversified medical technology conglomerates. Johnson and Johnson is aggressively pushing forward with its robotics ecosystem, while Medtronic is gaining regulatory clearances and commercial traction with its Hugo system. Despite the vast resources of these competitors, the entrenched nature of Intuitive Surgical makes hospital displacement an exceptionally difficult commercial endeavor.
Market Share and Dominance
Intuitive Surgical holds an overwhelming, undisputed leadership position in the global soft tissue robotic surgery market. While exact market share figures in such a monopolistic environment can be semantic, the company effectively controls the vast majority of all robotic-assisted soft tissue procedures globally. As of early 2026, Intuitive boasted a global installed base of over 11,395 da Vinci systems and over 1,000 Ion systems.
This installed base represents an immense geographic footprint that competitors must contend with. With nearly 17 million procedures performed historically on da Vinci platforms, the company systems have become the standard of care for procedures like radical prostatectomies and increasingly for hernia repairs and cholecystectomies. The sheer ubiquity of the da Vinci platform in teaching hospitals means that entire generations of surgical residents learn exclusively on Intuitive hardware, establishing a brand loyalty and clinical familiarity that defines the market structure.
The Competitive Moat
The competitive advantages shielding Intuitive Surgical are profound, centered primarily on prohibitive switching costs, scale, and an increasingly sticky digital ecosystem. The most formidable barrier to entry is the human capital investment required to master robotic surgery. Training a surgeon on a complex robotic system takes significant time and institutional resources. With nearly 90,000 surgeons globally trained on da Vinci systems, hospitals are highly disincentivized to switch to a competing platform, as doing so would require an immensely disruptive, costly, and time-consuming retraining period for their highest-revenue-generating personnel.
Scale serves as a secondary, yet equally powerful, moat. With over $10.1 billion in annual revenue and roughly $2.5 billion in free cash flow generated in 2025, Intuitive can fund massive research and development budgets that dwarf the combined robotics budgets of its peers. Thousands of engineers are dedicated solely to iterating on the platform. Furthermore, the volume of procedures allows Intuitive to amortize its fixed costs more efficiently, supporting pro forma operating margins near 39% despite persistent macroeconomic pressures.
Finally, the company has masterfully built a digital ecosystem that locks in institutional customers. The integration of 3D anatomical models, pre-operative planning software, real-time analytics, and digital learning applications creates powerful data-network effects. Hospitals rely on these analytics to monitor surgeon efficiency and patient outcomes. Replicating the physical robot is merely a baseline challenge for competitors; replicating the two decades of clinical data and the integrated software ecosystem is an entirely different magnitude of difficulty.
Industry Dynamics: Opportunities and Threats
The robotic surgery industry is characterized by several powerful secular tailwinds, offset by emerging clinical and macroeconomic headwinds. The primary opportunity lies in the continued penetration of general surgery. While urology and gynecology are mature markets for robotics, procedures like hernia repair, colorectal surgery, and cholecystectomy still possess significant runway for robotic adoption. Furthermore, the international market remains heavily underpenetrated. Intuitive has capitalized on regulatory quota expansions in China through its joint venture and has recently transitioned to direct distribution models in key European markets like Italy and Spain to capture higher margins.
Conversely, the rise of glucagon-like peptide-1 weight-loss medications poses a structural threat to bariatric procedure volumes. Intuitive management has acknowledged modest declines in bariatric surgeries as patients opt for pharmaceutical interventions over surgical gastric bypasses. While bariatric surgery is only one sub-segment of general surgery, it highlights how pharmaceutical innovation can suddenly disrupt surgical total addressable markets.
Additionally, macroeconomic pressures and hospital capital constraints present cyclical risks. Healthcare systems in markets like Japan and the United Kingdom frequently face government budget limitations, which can delay capital placements. In China, evolving provincial tender processes have increasingly favored local robotics suppliers, posing a localized pricing threat to Intuitive international expansion thesis.
Innovation Engine and New Growth Drivers
Intuitive Surgical growth trajectory is heavily reliant on continuous, clinical-first innovation. The most consequential development is the launch of the da Vinci 5, which saw a broad commercial rollout in the middle of 2025. The da Vinci 5 incorporates substantial technological leaps, most notably force feedback instrumentation. This allows surgeons to physically feel the tension and resistance of tissue, a feature designed to reduce tissue trauma and improve clinical outcomes. Early data indicates that utilization rates for the da Vinci 5 in the United States are tracking significantly higher than its predecessor, the da Vinci Xi, confirming strong market reception.
A major emerging growth driver is the company re-entry into the cardiac surgery space. In early 2026, Intuitive secured clearance from the Food and Drug Administration to use the da Vinci 5 in a variety of complex cardiac procedures, including mitral valve repairs. While initial cardiac procedures are limited to non-force feedback instruments, the measured rollout of specific cardiac tools later in 2026 is expected to unlock a highly complex, high-value surgical market that Intuitive had previously struggled to dominate.
Simultaneously, the Ion endoluminal system is becoming a formidable revenue driver in its own right. Designed for robotic-assisted bronchoscopy to perform minimally invasive lung biopsies, the platform experienced 39% procedure growth in the first quarter of 2026. As lung cancer screening protocols expand globally, the demand for precise, peripheral lung biopsies places the Ion system in an optimal position for sustained high-double-digit growth.
The Disruptors and New Entrants
While Intuitive has historically operated without peer, the landscape of new entrants is crystallizing into a tangible, though early-stage, threat. Johnson and Johnson is the most credible disruptor with its Ottava robotic surgical system. The Ottava platform, which evolved from the legacy Verb Surgical joint venture, differentiates itself through a table-mounted architecture and a unified open console design. In January 2026, Johnson and Johnson submitted Ottava to the Food and Drug Administration for de novo classification, targeting general surgery procedures within the upper abdomen. With a commercial timeline pointing toward a late 2026 or 2027 market impact, Ottava will lean heavily on Johnson and Johnson massive digital ecosystem partnership with Microsoft and its entrenched hospital contracting leverage.
Medtronic is also advancing its Hugo system, which utilizes a modular design allowing independent robotic arms to be moved from operating room to operating room. Hugo has achieved critical regulatory clearances outside the United States and is steadily making clinical progress domestically, with Medtronic focusing heavily on general surgery and gynecology. CMR Surgical, a privately held British company, continues to place its Versius system in international markets, competing primarily on price and a smaller physical footprint. However, none of these entrants have yet demonstrated the clinical superiority or ecosystem integration necessary to displace a functioning da Vinci program, relegating them primarily to greenfield hospital expansions rather than direct replacement cycles.
Management and Capital Allocation
The management track record at Intuitive Surgical is widely considered one of the finest in the medical technology sector, defined by conservative guidance, clinical rigor, and excellent capital allocation. A monumental leadership transition occurred in July 2025 when long-time Chief Executive Officer Gary Guthart stepped down to become Executive Chair. Under Guthart fifteen-year tenure, Intuitive evolved from a niche hardware manufacturer into a $10.1 billion digital and robotic ecosystem.
Dave Rosa, an Intuitive veteran of 29 years and the company ninth employee, was promoted to Chief Executive Officer. Rosa technical pedigree is impeccable; he founded the clinical engineering groups that developed the da Vinci single-port and Ion platforms. The market has received this transition highly favorably, viewing Rosa as the architect of the company current product pipeline.
Management approach to capital allocation is equally disciplined. Eschewing dividends entirely, the company channels its immense free cash flow into aggressive research and development and opportunistic share repurchases. In the first quarter of 2026 alone, Intuitive repurchased $1.1 billion of its own stock, a clear signal of internal confidence in long-term cash flow generation despite the premium valuation the market assigns the equity.
The Scorecard
Intuitive Surgical stands as a textbook example of an impenetrable economic moat fortified by deep clinical integration, immense switching costs, and recurring revenue economics. The successful commercialization of the da Vinci 5 platform, combined with an 86% recurring revenue profile, provides the company with remarkable financial visibility and operational leverage. While the emergence of credible soft tissue robotics platforms from Johnson and Johnson and Medtronic warrants monitoring, the multi-year retraining friction and Intuitive two-decade head start in clinical data generation make widespread hospital displacement highly improbable in the near to medium term.
The structural headwinds from glucagon-like peptide-1 medications on bariatric surgery and ongoing geopolitical supply chain friction represent manageable risks rather than existential threats. With Dave Rosa executing a seamless transition into the chief executive role, the company expansion into complex cardiac procedures and international markets offers extensive runway for continued top-line compounding. Intuitive Surgical remains the apex predator of the medical technology sector, commanding a monopolistic position that is continually reinforced by its own pace of clinical innovation.